22:14:01 EDT Thu 28 Mar 2024
Enter Symbol
or Name
USA
CA



Cybin Inc
Symbol CYBN
Shares Issued 165,520,533
Close 2022-06-06 C$ 0.95
Market Cap C$ 157,244,506
Recent Sedar Documents

Cybin to acquire DMT study from Entheon for $1M

2022-06-07 11:17 ET - News Release

Mr. Doug Drysdale reports

CYBIN ACQUIRES DMT CLINICAL STUDY FROM ENTHEON BIOMEDICAL

Through its wholly owned subsidiary Cybin IRL Ltd., Cybin Inc. has entered into an agreement to acquire a phase 1 N,N-dimethyltryptamine (DMT) study from Entheon Biomedical Corp. to accelerate the clinical development path for CYB004, Cybin's proprietary deuterated DMT molecule for the potential treatment of anxiety disorders.

The phase 1 EBRX-101 study, now named CYB004-E, is being conducted in the Netherlands at the Centre for Human Drug Research, a leading independent foundation specializing in innovative early-stage clinical drug research, in 50 healthy volunteers who smoke tobacco -- making it the largest phase 1 DMT clinical study conducted to date. Pending the close of the acquisition, the CYB004-E study is expected to yield essential safety and dosing optimization data and will replace Cybin's planned pilot study for CYB004 that was expected to commence in the third quarter of 2022. Entheon will continue to support the CYB004-E study and act as external consultant to Cybin.

"The most precious commodity in drug development is time and acquiring this robust phase 1 study already under way potentially accelerates the CYB004 development program by approximately nine months. The PK [pharmacokinetics] findings from the CYB004-E study should also help to inform the clinical path forward for this innovative and proprietary molecule," said Doug Drysdale, chief executive officer of Cybin. "This transaction also provides Cybin with access to a world-class research foundation and the privilege to work with the Entheon team, who offer a wealth of knowledge and expertise in this psychedelic class."

The purchase price of the acquisition is $1-million, a portion of which will be a deposit, with the balance payable on closing of the acquisition. Up to an additional $480,000 is payable for consulting services to be provided by Entheon for up to 12 months following the closing of the acquisition. Pursuant to the acquisition, the company will also enter into a data licence agreement with Entheon that will permit Entheon to access certain data to support the Entheon IQ program. The company expects the acquisition to close within 30 days, subject to the completion of certain conditions and obtaining all necessary approvals.

"With our recent IND [investigational new drug] filing for CYB003, we are quickly becoming a multiprogram clinical-stage company with four sponsored human trials under way in 2022. This is especially meaningful to our work to bring our innovative psychedelic-based therapies to people in need as quickly as possible. This is a truly exciting time for Cybin," concluded Mr. Drysdale.

About the CYB004-E study

The CYB004-E study is an adaptive, randomized, double-blind, placebo-controlled, single-ascending-dose study to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of a target-controlled intravenous infusion of DMT in healthy smokers.

Primary objectives:

  • Evaluate the safety of increasing doses of a single-dose continuous DMT infusion over 90 minutes;
  • Characterize the PK of a single dose of DMT administered continuously over 90 minutes;
  • Characterize the PD of a single dose of DMT administered continuously over 90 minutes;
  • Establish the minimum DMT dose required to produce a psychedelic effect.

Pending results from the CYB004-E study, Cybin plans to evaluate CYB004 delivered through intravenous (IV) and through inhalation to determine the clinical path forward. Based on preclinical results reported by Cybin in April, 2022, inhaled CYB004 demonstrated:

  • Approximately 2,000-per-cent improved bioavailability compared with orally administered DMT, which is known to have limited to no oral bioavailability;
  • Approximately 41-per-cent improved bioavailability compared with inhaled DMT;
  • Approximately 300-per-cent longer duration of effect when compared with IV DMT, indicating potential to extend therapeutic window;
  • Rapid onset of effect and similar low variability equivalent to IV DMT.

CYB004 is a new chemical entity for which a patent was issued by the U.S. Patent and Trademark Office in February, 2022. The allowed claims include a range of deuterated forms of DMT and 5-MeO-DMT. The composition of matter patent is expected to expire in 2041 before consideration of any patent term extensions.

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.